Synthesis and structure-activity relationships of novel anti-hepatitis C agents: N3,5′-cyclo-4-(β-D-ribofuranosyl)-vic-triazolo[4, 5-b]pyridin-5-one derivatives

Journal of Medicinal Chemistry

Volumn 48, Issue 20, 2005, Pages 6454-6460

  Wang, Peiyuan ^a   Du, Jinfa ^a   Rachakonda, Suguna ^a   Chun, Byoung Kwon ^a   Tharnish, Phillip M ^a   Stuyver, Lieven J ^a   Otto, Michael J ^a   Schinazi, Raymond F ^b   Watanabe, Kyoichi A ^a  

^a PHARMASSET INC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,5' CYCLO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 THIONE; 3,5' CYCLO 6 BROMO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 6 CHLORO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 (2 HYDROXYETHYLAMINO) 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 (DIMETHYLAMINO) 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 (ETHYLAMINO) 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 CYCLOPROPYLAMINO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 HYDROXYPROPYLAMINO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 METHOXYETHYLAMINO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 METHYL 4 (2,3 O ISOPROPYLIDENE BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 METHYL 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 METHYLAMINO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 3,5' CYCLO 7 PROPYLAMINO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; 4 METHYL 5 NITRO 1 (2,3,5 TRI O BENZOYL BETA DEXTRO RIBOFURANOSYL)PYRIDIN 2 ONE; 4 METHYL 5 NITRO 1 (BETA DEXTRO RIBOFURANOSYL)PYRIDIN 2 ONE; 7 AMINO 3,5' CYCLO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO [4,5 B]PYRIDIN 5 ONE; 7 N BUTYLAMINO 3,5' CYCLO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDIN 5 ONE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; BRIDGED COMPOUNDS; CELL LINE, TUMOR; HEPACIVIRUS; HUMANS; NUCLEOSIDES; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 26444599638     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058223t     Document Type: Article

References (14)

1. Alter, M. J.; Kruszon-Moran D.; Nainan, O. V.; McQuillan, G. M.; Gao F.; Moyer, L. A.; Kaslow, R. A.; Margolis, H. S. The prevalence of hepatitis C virus infection in the United states, 1988 through 1994. N. Engl. J. Med. 1999, 341, 556-562.
2. Zein, C. O.; Zein, N. N. Advances in therapy for hepatitis C infection. Microbes Infect. 2002, 4, 1237-1246.
3. Rosenberg, S. Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. 2002, 313, 451-464.
4. Collier, J.; Chapman, R. Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. BioDrugs 2001, 15, 225-238.
5. Di Bisceglie, A. M.; McHutchison, M. J.; Rice, C. M. New strategies for hepatitis C. Hepatology 2002, 285, 224-231.
6. 3,5′-Cyclo-4- (β-D-ribofuranosyl)-vic-triazolo[4,5-b]-pyridin-5-one, A Novel Compound with Potential Anti-hepatitis C Virus Activity. J. Med. Chem. 2004, 47, 6100-6103.
7. Pankiewicz, K. W.; Hirota, K.; Matsuda, A.; Watanabe, K. A. A synthesis of ψ-cytidine. Carbohydr. Res. 1984, 127, 227-233;
8. Watanabe, K. A.; Chu, C. K.; Reichman, U.; Fox, J. J. 2,5′-Anhydrouridine and 2,5′-anhydro-5-fluorouridine. One-step conversion of uridine and 5′fluorouridine into their corresponding 2,5′-anhydronucleosides. In Nucleic acid Chemistry. Improved and New Synthetic Procedures, Methods and Techniques; Townsend, L. B., Tipson, R. S., Eds.; John Wiley & Sons: New York, 1978; Vol. 1, pp 343-346.
9. Lynch, B. M.; Sharma, S. C. Synthesis, structural and conformational assignments, and conversions of pyridine and triazopyridine nucleosides. Can. J. Chem. 1976, 54, 1029-1038.
10. Stuyver, L. J.; McBrayer, T. R.; Tharnish, P. M.; Hassan, A. E. A.; Chu, C. K.; Pankiewicz, K. W.; Watanabe, K. A.; Schinazi, R. S.; Otto, M. J. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol. 2003, 77, 10689-10694.
11. Stuyver, L. J.; Whitaker, T.; McBrayer, T. R.; Hernandez, B. I.; Lostia, S.; Tharnish, P. M.; Ramesh, M.; Chu, C. K.; Shi, J.; Jordan, R.; Watanabe, K. A.; Rachakonda, S.; Otto, M. J.; Schinazi, R. F. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C virus in culture. Antimicrob. Agents Chemother. 2003, 47, 244-254.
12. Blight, K. J.; Kolykhalov, A. A.; Rice, C. M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290, 1972-1974.
13. Schinazi, R. F.; Sommadossi, J. P.; Saalmann, V.; Cannon, D. L.; Xie, M.-W.; Hart, G. C.; Smith, G. A.; Hahn, E. F. Activity of 3′-azido- 3′-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1990, 34, 1061-1067.
14. Stuyver, L. J.; Lostia, S.; Adams, M.; Mathew, J.; Pai, B. S.; Grier, J.; Tharnish, P.; Choi, Y.; Chong, Y.; Choo, H.; Chu, C. K.; Otto, M. J.; Schinazi, R. F. Antiviral activities and cellular toxicities of modified 3′,3′-dideoxy-3′, 3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 2002, 46, 3854-3860.